The European Commission approved SKYRIZI for pediatric psoriasis treatment.
2 reports, 1 independent
Updated Jun 23
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The European Commission approved SKYRIZI for pediatric psoriasis treatment.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- A drug application from AbbVie is currently seeking a positive opinion from the CHMP, with the final decision impacting market access in the EU.Sub-event
EC approved SKYRIZI for pediatric psoriasis use.1 source
Keep exploring
The entities involved
-
AbbVie
pharmaceutical company
-
European Commission
executive branch of the European Union